Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Investigating the recent data from the Phase 2 VISIONARY-MS clinical trial of CNM-Au8 in patients with multiple sclerosis

Ticker(s): CLNN

Who's the expert?

Institution: WUSTL

Associate Professor of Neurology and Director of Multiple Sclerosis Clinic at WUSTL.
Currently treats 450 patients with Multiple Sclerosis (Dedicated MS specialist).
Has prescribed Tecfidera to 75 patients and Vumerity to 10 patients.
Extensive MS investigator clinical trial experience.

Interview Goal

to discuss the current standard of care and the potential of CNM-Au8, a treatment being developed by Clene Nanomedicine for repair and remyelination in multiple sclerosis.

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.